It has been reported that dual therapy (anti-CTLA-4 and anti-PD-1/PD-L1) increased the rate of myocarditis than monotherapy (1.22% vs. 0.54%; 5.8% vs. The gene discussed is CTLA4; the disease is myocarditis.